title: The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention.
abstract: The platelet to lymphocyte ratio (PLR) has been investigated as a new predictor for cardiovascular risk. The aim of the present study was to investigate the prognostic role admission PLRat admission in predicting in-hospital and early mortality in patients presenting with ST segment elevation myocardial infarction (STEMI). A total of 639 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (PCI) were included. The study population was divided into tertiles on the basis of PLR values at the admission. A high PLR (N = 213) was defined as a value in the upper third tertile (PLR >174.9) and a low PLR (N = 426) was defined as any value in the lower two tertiles (PLR ≤ 174.9). The patients were followed for clinical outcomes for up to 6 months after discharge. In Kaplan-Meier survival analysis, the rate of 6-month all-cause deaths was 7% in the high PLR group versus 3% in the low PLR group (P = 0.03). In multivariate analyses, a significant association was noted between high PLR levels and the adjusted risk of 6-month all-cause deaths (odds ratio = 2.51, 95% confidence interval = 1.058-5.95; P = 0.03). PLR is a readily available clinical laboratory value associated with 6-month all-cause death in patients with STEMI who undergo primary PCI.
authors.affiliation: aDepartment of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Center, Istanbul bDepartment of Cardiology, Mehmet Akif Ersoy Cardiovascular and Thoracic Surgery Center, Training and Research Hospital, Istanbul cDepartment of Cardiology, Marmara University, School of Medicine, Istanbul dDepartment of Cardiology, Ankara Numune Training and Research Hospital, Ankara eDepartment of Cardiology, Vakif University, School of Medicine, Istanbul fKadirli State Hospital Clinic of Cardiology, Osmaniye, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Ugur
authors.forename: Mehmet
authors.initials: M
authors.lastname: Gul
authors.forename: Mehmet
authors.initials: M
authors.lastname: Bozbay
authors.forename: Gokhan
authors.initials: G
authors.lastname: Cicek
authors.forename: Huseyin
authors.initials: H
authors.lastname: Uyarel
authors.forename: Bayram
authors.initials: B
authors.lastname: Koroglu
authors.forename: Mahmut
authors.initials: M
authors.lastname: Uluganyan
authors.forename: Serkan
authors.initials: S
authors.lastname: Aslan
authors.forename: Eyyup
authors.initials: E
authors.lastname: Tusun
authors.forename: Ozgur
authors.initials: O
authors.lastname: Surgit
authors.forename: Emre
authors.initials: E
authors.lastname: Akkaya
authors.forename: Mehmet
authors.initials: M
authors.lastname: Eren
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001792:Blood Platelets / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D016017:Odds Ratio; D010976:Platelet Count; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome